gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin zynteglo vs zolgensma
highlight week june june buy chardan top pick announc
submiss ind topic gene therapi gt autosom recess
congenit ichthyosi arci compani plan initi phase i/ii trial arci would make
krystal clinic asset bluebird bio unrat announc price lentiviral-bas gt zynteglo
mm success year year payment made success zynteglo last week
receiv condit market author ema treatment transfusion-depend beta-thalassemia
tdt mm approxim mm price tag zolgensma mm avexi
novarti unrat compani gt spinal muscular atrophi sma bluebird bio unrat present data
european hematolog associ eha annual meet amsterdam group on-going phase i/ii trial
lentiglobin sickl cell diseas scd bluebird bio also present updat data differ
trial lentiglobin zynteglo tdt edita medicin buy present preclin data eha ex vivo gene
edit program call scd beta thalassemia given recent approv unrat bluebird
bio zynteglo tdt eu along program crispr buy
unrat /sanofi unrat alreadi clinic edita might see best-in-class potenti
look forward june june june european refer network neurolog
diseas ern-rnd annual meet take place siena itali program includ repres uniqur
buy june peripher nerv societi pn host annual meet genoa itali program
includ repres unrat buy
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
chardan discontinu use rate categori compani research univers accordingli chardan
drop coverag rgl inc
xcur buy pt intrigu data research june naka
research northwestern univers present data american societi clinic oncolog annual
meet phase first-in-human studi spheric nucleic acid -base therapeut
glioblastoma patient signific treatment-rel toxic observ evid seen
cross blood-brain barrier
believ data posit read-across exicur therapeut
krystal announc submiss ind topic gt autosom
recess congenit ichthyosi arci krystal plan initi phase i/ii trial arci
pleas refer import disclosur inform regul analyst certif found page report
conserv model mm risk-adjust sale npv/share mean could
becom futur driver chardan price target upgrad clinic progress
reiter high convict krystal base potenti krystal end interest program
clinic compani strong intern manufactur capabl broader platform easi
replic would surpris krystal market cap cross billion year ahead
buy increas ex vivo effort start studi scd june livshit
edita medicin present addit preclin data eha ex vivo gene edit program scd beta
thalassemia addit announc enter ind-en studi major new point eha
updat optim guid rna nucleas pair increas fetal hemoglobin hbf level
maintain edit effici select candid ind-en studi
us develop broadli signal continu edita expans shift focu ex vivo effort
outlin chardan gene edit framework cgef continu view ex vivo program strong driver
valuat gene edit compani therefor await visibl edita ipsc-deriv program particular
edita approach differenti hbf level encourag difficult discern mean
versu program note commentari data decemb research comparison
gene edit program difficult due differ experiment design hemoglobin metric report
genet medicin news june june
unrat announc initi pi/ii trial aavhsc-bas gt phenylketonuria june
neutral announc dose cohort pi trial aav-bas gt wamd june
rgl unrat announc addit board director june
unrat announc ind clearanc tcr t-cell tx use sleep beauti platform june
egenesi privat announc appoint ariel jasi cbo gener counsel june
ly fp unrat announc patient treat pii/iii trial aav-bas gt mp iiia june
buy report result provid corpor updat june
unrat announc appoint dario scimeca gener counsel june
unrat appoint joan herman board director june
columbia univers publish transposon-encod nuclease-defici crispr-ca system june
unrat announc broader publicli fund access aso spinraza ontario june
arct buy announc approv isra court redomicil us june
buy announc appoint vice-president regulatori affair head patient advocaci june
curevac privat receiv patent intratumor administr rna june
neutral announc new addit senior leadership team june
gsk unrat announc collabor univers california crispr technolog june
glaxosmithklin announc collabor establish laboratori genom research lgr
research develop new product use crispr effort led dr jennif doudna ucb dr
jonathan weissman ucsf focu immunolog oncolog neurosci gsk contribut
mm year includ fund full-tim univers employe full-tim gsk employe
lgr also incorpor gsk artifici intellig machin learn group order build comput
pipelin analyz data furthermor goal lgr autom exist crispr approach order
work scale dr weissman explain access give scientist opportun advanc
research way would hard lab
collabor us repres yet anoth signal big cap pharma interest gene edit therapeut
research applic last week unrat announc acquisit exon
privat expans collabor gene edit compani crispr buy
tessa tx privat establish joint ventur csgkc cell therapi cancer june
umrx unrat announc addit new member leadership team june
page
freelin privat announc ceo transit final seri tranch mm june
stoke tx privat announc appoint jennif burstein board director june
unrat present data eha group phase i/ii trial lentiglobin scd june
bluebird bio eha annual meet present data phase i/ii trial lentiviral-bas gt
lentiglobin sickl cell diseas scd march patient enrol patient treat
lentiglobin group median post-treat follow-up month
patient least month follow-up rang gt-deriv hemoglobin product
g/dl total unsupport hemoglobin hb level rang g/dl patient least month
follow-up median concentr continu increas account total hb base
new exploratori assay investig determin sampl patient least month post-treat
averag least percent patient red blood cell rbc express
acut chest syndrom ac seriou vaso-occlus crisi voc report marker hemolysi
trend toward normal level sae observ non-seri ae hot flush report resolv
group bluebird bio use refin manufactur process design increas vector copi number vcn
improv engraft ex vivo genet modifi cell encourag data group vs prior cohort us
underscor import optim manufactur process highlight april commentari
unrat present data eha differ trial lentiglobin tdt june
bluebird bio present updat northstar pi/ii trial new data on-going
piii trial piii trial lentiglobin zynteglo tdt
studi patient without genotyp treat lentiglobin evalu
patient year post-treat achiev transfus independ maintain median weight
averag hb g/dl rang g/dl bone marrow sampl taken patient month
follow-up patient improv myeloid erythroid ratio measur dyserythropoesi seen
studi patient genotyp mutat treat
lentiglobin april patient evalu transfus independ achiev maintain transfus
independ month post-treat total hb g/dl patient stop transfus
least month reach month post-treat level least g/dl
unrat announc price gt zynteglo mm year june
bluebird bio present updat commerci launch zynteglo follow receipt ema condit
market author june zynteglo price mm due year due
follow year success treatment
mm approxim mm total price tag zynteglo less mm price aav-bas
gt zolgensma avexi novarti unrat compani approv sma us may
howev bluebird bio model afford greater payment flexibl outcomes-bas agreement
price subject outcom remain seen model feasibl zynteglo approv
us case note regard zolgensma approv outcomes-bas agreement particular like
one zynteglo show compani confid gt durabl
compani mention report
page
page
select catalyst genet medicin coverag
figur alnylam arrowhead dicerna meira gtx expect initi trial
provid program updat phase i/ii valen trial crigler-najjar syndrom
select optim dose xlmtm
dcr-phxc initi long-term registr roll-ov studi ph
file ind cta pomp diseas
aro-aat initi phase ii/iii studi liver diseas
releas cgmp manufactur phase i/ii studi
initi phase i/ii trial
aav-rpgr prelim dose escal data phase i/ii trial xlrp
initi trial malign
complet phase i/ii studi dystroph epidermolysi bullosa deb
top-lin phase ii data treat deb patient
complet ind-en studi diseas
dose patient phase studi mp
lumasiran initi illuminate-b -c phase trial
givosiran file applic ahp
provid updat phase i/ii studi hemophilia
report phase i/ii data
page
select catalyst genet medicin coverag
file ind pomp diseas
inclisiran report top-line data orion studi hypercholesterolemia
initi phase i/ii clinic trial huntington diseas
report dose escal data pi/ii trial achm/xlrp
report preliminari data phase i/ii studi batten diseas
initi phase i/ii trial dmd
submit ema lhon
report interim efficaci readout phase oval trial ovarian cancer
xlrp report interim data expans arm phase i/ii trial xlrp
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
provid earli data cohort phase i/ii pioneer trial n- rp
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi phase trial dystroph epidermolysi bullosa deb
initi phase i/ii trial autosom recess congenit ichthyosi
file ind ornithin transcarbamylas over-the-counter defici
report interim phase i/ii data rix nidcr/nih
initi dose phase trial hemophilia
initi phase i/ii trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
updat dose escal pi/ii ignit trial dmd
provid updat initi safeti studi hemophilia without inhibitor
 aro-enac file clear cell renal cell carcinoma cystic fibrosi
 fc initi phase ii/iii trial newli diagnos glioblastoma
 fc safeti activ readout phase ib trial met solid tumor
submit ind methylmalon acidemia mma
present preclin data new gt program fabri pomp defici
initi phase i/ii trial sjogren syndrom
file ind initi phase i/ii trial al
file ind initi phase i/ii trial wet
 file ind al huntington diseas program
provid follow-up data piib dose-confirm studi hemb
present top-lin data phase i/iia clinic trial wet
initi pivot trial
 fc report final analysi phase trial rhgg
declar develop candid aml
figur alnylam/mdco meira gtx solid uniqur expect import data read-out
page
select catalyst outsid genet medicin coverag
file ind rett syndrom
initi phase dose escal studi danon diseas
initi phase i/ii trial leukocyt adhes deficiency-i
initi phase trial recess dystroph epidermolysi bullosa
nsr-rpgr provid follow-up data phase xiriu dose escal studi xlrp
file ind inherit amyotroph later sclerosi
begin patient dose phase trial
initi pivot phase trial rdeb
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
dtx provid pi/ii cohort data glycogen storag diseas type ia gsdia
valrox present full piii top-line data hem
nsr-rpgr provid prelim data expans cohort phase ii/iii trial xlrp
zolgensma anticip approv eu
nsr-rpgr report follow-up data open label dose escal phase xiriu studi
valrox submit bla pend fda feedback hemophilia
begin dose patient investigator-sponsor phase i/ii trial cystinosi
initi phase i/ii trial type gaucher diseas
bmn file ind phenylketonuria pku
initi phase ib trial beta-thalassemia
initi phase ii/iii trial dmd
initi phase studi pyruv kinas defici pkd
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
rituximab report preliminari phase cohort expans data r/r nhl
micro-dystrophin initi pivot trial duchenn muscular dystrophi
hmaxi-k initi phase ii studi overact bladder
initi phase i/ii trial gangliosidosi
zolgensma complet strong phase trial pre-symptomat sma type
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma fibrocel buy lysogen oncosec medic oxford biomedica buy vbl neutral
figur select price movement week end june vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm appli genet therapytickerratingccm ptupsideclosechang changemc mm dicerna gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note although avx acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
cap refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrated/nr name rgl model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti ntech curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrated/nr name model current market
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan poseida recombinet
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
price prv
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
page
date fda rpdd
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
